To answer these questions and to further elucidate the correlation of purinergic signaling molecule expression and disease trajectories, we analyzed the CD39, CD73, P2X4, and P2X7 expression levels in NSCLC tumor samples of 139 patients. The gene discussed is P2RX7; the disease is non-small cell lung carcinoma.